Study of AT-752 in Healthy Subjects
A First-in Human, Randomized, Double-blind, Placebo Controlled Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AT-752 in Healthy Subjects
Sponsor: Atea Pharmaceuticals, Inc.
This PHASE1 trial investigates Dengue and is currently completed. Atea Pharmaceuticals, Inc. leads this study, which shows 6 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Nov 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Sep 2021 — Nov 2022 [monthly]
Recruiting PHASE1
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Feb 2021 — Jun 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Atea Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .